| Press Release
BluMaiden Biosciences Pte Ltd
Three Shenton Way #15-01
T (65) 9720 0753
July 14, 2021
Michael Tillmann Joins BluMaiden Biosciences as Investor and as Appointed Chairman of the Board
Singapore – BluMaiden Biosciences Pte Ltd, a Singapore headquartered early-stage biotechnology platform company, announced today that well-known life-sciences investor Michael Tillmann has joined the Company as angel investor and member of the board. Mr. Tillmann will also succeed co-founder Robert Meyer, Managing Partner of Angsana Investments, as Chairman of the board.
Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry. Having served Roche Diagnostics as its Asia Pacific and North America CEO with a seat in the Roche Global Executive Board, Mr. Tillmann has been running his own bio-tech incubator Amatar Group since 2010. In this role, he also founded Vela Diagnostics Ltd, which was acquired by the Luye Lifescience Group in 2020.
“Michael brings highly valuable and relevant experience to BluMaiden. His accomplishments in the fields of molecular diagnostics and next-generation sequencing technologies, coupled with his experience from multiple supervisory and advisory board roles, will help guide BluMaiden to achieve its targets in preventing and treating human diseases,” says Dr. Damien Keogh, Founder and Chief Executive Officer of BluMaiden Biosciences.
Robert Meyer added: “I am delighted that we have been able to win the confidence of Michael both as a financial sponsor and incoming Chairman of BluMaiden. I couldn’t think of a better pair of hands to pass the baton as Chairman of the Board to, and I will continue to support BluMaiden as an active investor and board member. ”
BluMaiden uses proprietary machine learning and artificial intelligence approaches through integrated computational biology platforms to explore the universe within the human microbiome. The company is focused on research, development, and future commercialization of breakthrough microbiome-derived solutions for disease tracking, prevention, and therapeutics. To deepen its drug discovery research and development and bring its health-tech business to global markets, the company is targeting a significant seed round raise in 2022.
The BluMaiden board now comprises Dr. Damien Keogh, Michael Tillmann, Robert Meyer, and Dr. Terence Kelly. The BluMaiden Biosciences Scientific Advisory Board includes University Distinguished Professor Kim Lewis FAAAS, Distinguished Laureate Professor Nicholas Talley AC FAHMS and Professor Stephen Simpson, AC FRS FAA.
About BluMaiden Biosciences
BluMaiden Biosciences is an early-stage biotechnology company headquartered in Singapore with the goal of developing microbiome-derived molecular
therapeutics for patients with unmet medical needs. We have integrated a unique computational population-scale data acquisition platform with a therapeutics discovery platform.
BluMaiden Biociences Pte Ltd
Get In Touch
Whether you are a medical practitioner, a patient or would like to learn more, we would love to hear from you